Business
ADMA Biologics Provides Update on Global Intellectual Property Portfolio
Extends Existing U.S. Patent with Granted European Patent for Treatment and Prevention of S. Pneumococcal Infections with a Hyperimmune Globulin Reinforces
About this update from Adma Biologics Inc
[{"type":"text","content":"Extends Existing U.S. Patent with Granted European Patent for Treatment and Prevention of S. Pneumococcal Infections with a Hyperimmune Globulin Reinforces Existing and Pending IP that Provides for ‘Spiking’ IG Pools with Monoclonal Antibodies to Create Novel Hyperimmune Globulins RAMSEY, N.J. and BOCA RATON, Fla., Dec. 09, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that the European Patent Office (EPO) has issued European Patent No. 3375789, to the Company. This patent relates to the treatment and prevention of S. pneumonia infections, and in particular, to standardized hyperimmune globulins containing elevated antibody titers for a plurality of S. pneumoniae serotypes. This EPO granted patent complements ADMA’s existing U.S. Pat. Nos. 10,259,865 and 11,084,870. “This European patent, which augments ADMA’s existing U.S. patent estate, highlights the Company’s emerging position as a thought leader in the development and commercialization of hyperimmune globulins which, we believe, will attract additional collaborators interested in pursuing these areas of significant unmet medical need,” stated Adam Grossman, President and Chief Executive Officer of ADMA. “The EPO’s issuance of the S. pneumonia patent, together with our previously granted U.S. patents, provides protection for the potential development of a S. pneumonia hyperimmune globulin. Despite widespread availability of U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)-approved vaccines, all-cause pneumonia is among the leading causes globally of vaccine preventable illness and deaths, particularly among vulnerable patient populations, including the immune compromised and the elderly. It is in this patient population that we believe a pneumococcal hyperimmune globulin will find significant medical utility and prove to be a favorable end-market if successfully developed.” Mr. Grossman continued: “ADMA continues to aggressively pursue its proprietary, therapeutic technologies and associated intellectual property (IP). In addition to its marketed and pipeline hyperimmune respiratory syncytial virus (RSV) immune globulin (IG) and hyperimmune S. pneumonia ...